key: cord-0763573-njhlfoss
authors: Kamstrup, Peter; Sivapalan, Pradeesh; Eklöf, Josefin; Hoyer, Nils; Ulrik, Charlotte Suppli; Pedersen, Lars; Lapperre, Therese S.; Harboe, Zitta Barrella; Bodtger, Uffe; Bojesen, Rasmus Dahlin; Håkansson, Kjell EJ; Tidemandsen, Casper; Armbruster, Karin; Browatzki, Andrea; Meteran, Howraman; Meyer, Christian Niels; Skaarup, Kristoffer Grundtvig; Lassen, Mats Christian Højbjerg; Lundgren, Jens D.; Biering-Sørensen, Tor; Jensen, Jens-Ulrik Stæhr
title: Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study
date: 2021-06-01
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.076
sha: c028b94a3f33f4d26510bf6dc4703c2e5bcf2d94
doc_id: 763573
cord_uid: njhlfoss

Objective Hydroxychloroquine has been proposed as a primary prophylactic agent against COVID-19. We aimed to investigate if patients treated with hydroxychloroquine for a non-SARS-CoV-2-indication had a lower risk of verified infection with SARS-CoV-2, compared with matched controls. Methods A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e. both during and before SARS-CoV-2 was confirmed in Denmark) matched by age and sex with controls. Data were collected using the Danish national registries containing complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results A total of 5,488 hydroxychloroquine-users were matched with 54,486 non-users. At baseline the groups differed on diagnoses of pulmonary, cardiovascular, renal,gastrointestinal / metabolic disease and dementia as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indication was not associated with any change in confirmed SARS-CoV-2 [HR of 0.90 (95% Confidence Interval 0.76-1.07)] This result was robust in the propensity-score matched sensitivity analysis. Conclusion Our study, which is the largest to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.

microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection.

A total of 5,488 hydroxychloroquine-users were matched with 54,486 non-users. At baseline the groups differed on diagnoses of pulmonary, cardiovascular, renal,gastrointestinal / metabolic disease and dementia as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indication was not associated with any change in confirmed SARS-CoV-2 [HR of 0.90 (95% Confidence Interval 0.76-1.07)] This result was robust in the propensity-score matched sensitivity analysis.

Our study, which is the largest to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of

CoV-2 (Severe acute respiratory syndrome corona virus 2) in infected vero-cells. , Yao et al., 2020 This contributed to the hypothesis that such drugs could be used as prophylaxis of SARS-CoV-2 infection and for treatment of patients with J o u r n a l P r e -p r o o f . Hydroxychloroquine is used for long-term treatment of several rheumatic diseases, the safety profile of the drug is favorable (Ponticelli and Moroni, 2017, Ruiz-Irastorza et al., 2010) and the cost is low, (Ponticelli and Moroni, 2017) which is a key point when facing a pandemic.

Five randomized clinical trials have demonstrated a neutral signal of treatment with hydroxychloroquine in hospitalized patients with COVID-19.(Abd-Elsalam et al., 2020 , Consortium et al., 2020 , Group et al., 2020 , Self et al., 2020 , Tang et al., 2020 Additionally, three randomized clinical trials reported no benefit of hydroxychloroquine as a post-exposure prophylactic agent, two of these against COVID-19(Boulware et al., 2020 , Mitjà et al., 2020 and the latter against PCR-verified SARS-CoV-2 infection. (Barnabas et al., 2020) Hydroxychloroquine has likewise been explored as a primary prophylactic agent against COVID-19 disease by two randomized trials, however, both were stopped too early to reach a firm conclusion. (Abella et al., 2020 , Rajasingham et al., 2020 Currently, four epidemiological studies investigating the primary prophylactic effect of hydroxychloroquine for SARS-CoV-2 infection have been identified. (Bae et al., 2021 , Ferreira et al., 2021 , Gendelman et al., 2020 , Jung et al., 2020 Three of these reports no effect, (Bae et al., 2021 , Gendelman et al., 2020 , Jung et al., 2020 whereas the largest report a reduced risk of SARS-CoV-2 for persons with a chronic hydroxychloroquine use. (Ferreira et al., 2021) A recent meta-analysis concluded that even though there is a further need for evidence on the use of hydroxychloroquine in prophylaxis of COVID-19. (Singh et al., 2021) With this study, we investigated, in a large population-based cohort with substantially more events than in the hereto published studies, whether persons treated with hydroxychloroquine prior to the pandemic had a lower risk PCR-confirmed SARS-CoV-2 infection compared with age and sex matched controls.

J o u r n a l P r e -p r o o f

We conducted a cohort study based on nationwide Danish registry data. We collected data from four registries: i) the Danish National Patient Registry which contains information on all admissions to Danish hospitals and hospital outpatient specialist clinic visits, (Schmidt et al., 2015) ii) the National Prescription Registry which contains information on all prescriptions dispensed in Danish pharmacies (coded according to the Anatomical Therapeutic Chemical (ATC) classification system), (Pottegard et al., 2017) iii) The Danish Central Personal Registry which contains information on citizens of Denmark, e.g. age, sex, and vital status. (Schmidt et al., 2014) iv) the Danish Microbiology Database where the Danish Departments of Clinical Microbiology (Voldstedlund et al., 2014) and Statens Serum Institut carried out laboratory analysis, registration and release of the national SARS-CoV-2 surveillance data for the present study.

All patients residing in Denmark who collected a prescription for hydroxychloroquine (ATC P01BA02) in 2020 as well as 2019 (i.e. initiated treatment before the pandemic emerged in Denmark) were included in the study. This approach was used to eliminate any impact of hydroxychloroquine use in attempts to treat COVID-19. Each recipient was matched randomly by birth year and sex with up to ten non-treated controls by the Danish Health Data Authority. Information about comorbidities was obtained from the Danish National Patient Registry. Comorbidities were collected as classified in the Charlson comorbidity index. (Quan et al., 2005) Grouping of comorbidities were done as follows: Cardiovascular disease (CVD) was a merge of heart failure, ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. Gastrointestinal and metabolic disease was a merge of diabetes with and without complications, mild-, moderate-and severe liver diseases, and J o u r n a l P r e -p r o o f peptic ulcer disease. Cancer was a combination of any malignancy (except malignant neoplasm of skin) and solid metastatic tumor. Pulmonary disease was defined as per the Charlson comorbidity index with additionally the interstitial pulmonary diseases included.

Comorbidities included in this study and their grouping are illustrated in the supplemental data (Supplemental Table S1 ). Only comorbidities or groups of comorbidities with a prevalence among the study population of more than or equal to 5% was included in the study.

We collected diagnoses on ventricular tachycardia, ventricular fibrillation and Torsades de Pointes tachycardia for assessment of safety. 

Hydroxychloroquine was the intervention investigated. To avoid bias we analyzed the users of the drug in both 2019 as well as in 2020. Additionally, controls who started hydroxychloroquine in 2020 were excluded (n=11).

The primary outcome measure was a PCR or antigenic verified SARS-CoV-2 infection during the study period (27 th of February to 27 th of November 2020).

Secondary outcome was hospitalization for more than 12 hours within 14 days of a positive SARS-CoV-2-test.

Statistical analyses were performed with Statistical Analysis Software 9.4 (SAS). Baseline comparisons of categorical data, as well as the crude comparison on SARS-CoV-2 in the two groups, were done using a Chi-square test, where the expected observations were five or more. When expected observations were less than five, Fisher's exact test was performed. In the case of continuous data, baseline comparisons were done using t-test or non-parametric tests, depending on the distributions.

The incidence of positive SARS-CoV-2 test was compared between cases and controls, using an adjusted Cox-proportional hazard regression analysis. Except for rheumatological disorders (a common indication for hydroxychloroquine), adjustments were made for age, sex, admission in the year prior to the study, and possible confounding diagnoses and pharmaceutical treatments with a prevalence among the study population of more than or equal to 5% (pulmonary disease, CVD, gastrointestinal / metabolic disease, cancer, methotrexate, systemic corticosteroids, sulfasalazine), as presented in Table 1 .

For sensitivity analysis, a Greedy matched propensity-score matching with a case/control ratio of 1:3 was performed via SAS 9.4 'PROC PSMATCH'. The same variables used for adjusting in the Cox-proportional hazards regression analysis were used for matching.

Matching was based on the logit of the propensity-score and with a caliper of 0.25 and we used an extended common support region as per default setting in the SAS procedure. To investigate the secondary outcome of hospital admissions, logistic regression analysis was applied, controlling for the previously mentioned parameters.

To account for differences in healthcare seeking behavior among patients, subgroup analysis was performed on the primary population, using only persons who had a SARS-CoV-2 test performed in the study period.

Furthermore, an adjusted Cox proportional hazards analysis was performed on the group of all recipients of hydroxychloroquine in 2019, with adjustment for the previously mentioned parameters. Model control investigating the proportional hazards assumption and test for linearity was performed to validate the Cox proportional hazards regression. If linearity was not fulfilled the model was run with the variable converted to ordered categorial variables based on the median and interquartile range (IQR) to ensure the lack of linearity had no effect on the result.

Specific interaction analysis was done for hydroxychloroquine and systemic corticosteroids, methotrexate and sulfasalazine.

The study is approved by the Danish Data Protection Agency: File number P-2020-537. In Denmark, retrospective use of register data does not require ethical approval or patient consent.

Data was only available for analyses on closed servers via the Danish Health Data Authority.

Reporting was carried out in accordance with the STROBE guidelines. (von Elm et al., 2008) J o u r n a l P r e -p r o o f

The hydroxychloroquine treatment group consisted of 5,488 persons, and these were matched with 54,846 individual non-treated controls as shown in Figure 1 . The baseline characteristics are presented in Table 1 Table S2 for the underlying data).

There was no difference in ventricular tachycardia (p=0.37), ventricular fibrillation (p=0.64) or Torsades de Pointes tachycardia (p=0.58) between the two groups.

The proportional hazards' assumption for the Cox regression was met. Linearity was not J o u r n a l P r e -p r o o f confirmed for age, so this variable was tested as a categorical variable in four categories, which did not change the results (Supplemental Data, Table S3 ). No interaction was found between hydroxychloroquine and either systemic corticosteroids, methotrexate or sulfasalazine.

The sensitivity analysis was a propensity-matched cohort, in which we confirmed the main finding: HR 1.01 (CI 0.92 -1.31). The baseline characteristics of the propensity-matched cohort are displayed in Table 1 .

Our secondary outcome of hospitals admissions within 14 days of SARS-CoV-2 positivity (Supplemental Tables S4, S5 and Figure S1 ) was an infrequent event both in the hydroxychloroquine group and among controls (n=175). The result was neutral, however limited by a lack of power: Odds ratio (OR): 1.44 (95% CI 0.78-2.65).

The subgroup consisting of all persons tested for SARS-CoV-2 in the study period also confirmed the primary analysis (HR 0.88 (CI 0.74-1.05). (Supplemental Table S6 , Figure S2 Table   S7 , Figure S3 )By the nature of the Danish registries, the study had a 100.0% follow-up on both the primary and secondary outcomes.

The present analysis, based on nationwide data and with complete follow-up for confirmed SARS-CoV-2 infection, we could not find any beneficial effect of hydroxychloroquine for primary prophylaxis against infection with SARS-CoV-2.

The result was robust and the signal remained unchanged in a propensity-matched cohort sensitivity analysis. This was also the case in the subgroups where we analyzed all SARS-CoV-2 tested persons and hydroxychloroquine recipients in 2019, respectively. Neither could we find any prophylactic effect of the drug regarding hospital admission following confirmed SARS-CoV-2, but the latter analysis was limited by a lack of power.

We observed a lower incidence of SARS-CoV-2 positivity with increasing age. This is likely to be a result of the social behavior of these groups, especially considering, that we also found a higher risk of admission amongst the positive patients increasing with age, as previously reported. (Ioannou et al., 2020 , Reilev et al., 2020 In congruence with our results, three epidemiological studies did not find any difference in SARS-CoV-2 risk between persons using hydroxychloroquine and others. (Bae et al., 2021 , Gendelman et al., 2020 , Jung et al., 2020 These studies were, however, limited by few events in the hydroxychloroquine groups (n = three to sixteen) and thus most likely insufficient power. A larger observational study from Portugal, reporting a decreased risk of SARS-CoV-2 for people receiving chronic hydroxychloroquine treatment, (Ferreira et al., 2021) by crosslinking their national databases on drug-prescription, obligatory notifiable diseases, and a database containing all SARS-CoV-2 tests performed. Although interesting, the study is limited by lack of important information on the subjects, e.g. comorbidities, which in turn could affect the social behavior.

So far, two randomized controlled trials investigating hydroxychloroquine as primary prophylaxis for COVID-19 have been performed. (Abella et al., 2020 , Rajasingham et al., 2020 Both trials were performed using healthcare workers as subjects. Abella et al. (Abella et al., 2020) investigated a dose of 600 mg daily, which was higher than the recommended daily dose for rheumatological disorders, whereas Rajasingham et al.(Rajasingham et al., 2020) used two different dosing regimens with either 400 mg once or twice weekly. Both these J o u r n a l P r e -p r o o f RCTs were terminated prematurely with very few events and are consequently inconclusive, but do not conflict with our results.

Post-exposure prophylactic properties of hydroxychloroquine were investigated by Boulware et al. (Boulware et al., 2020) and Mitjà et al.(Mitjà et al., 2020) against COVID-19, which both could not demonstrate any effect on the occurrence of the disease. The study by Boulware et al. was limited by a lack of microbiological verification on all subjects and by using a short term but high dosing regimen. (Boulware et al., 2020) This was not a limitation in the others study which had PCR-verified SARS-CoV-2 as outcome, however, their inclusion period after contact of up to seven days may have limited the study. (Mitjà et al., 2020 ) Whereas a recent study investigated the post-exposure prophylactic abilities of hydroxychloroquine against PCR-verified SARS-CoV-2 infection, without the beforementioned limitations, reaching the same conclusion. (Barnabas et al., 2020) The WHO has released a living guideline on drugs to prevent COVID-19, which makes a strong recommendation against hydroxychloroquine as prophylaxis against COVID-19. (Lamontagne et al., 2021) On the other hand, Singh et al. recently published a systematic review and meta-analysis on the prevention and treatment of COVID-19 with hydroxychloroquine, concluding that there is a further need for evidence on prevention. (Singh et al., 2021) Two pre-print systematic reviews and meta-analyses on randomized clinical trials has investigated hydroxychloroquine as prophylaxis against COVID-19. The first showed a pooled risk ratio of SARS-CoV-2 of 0.86 (95% CI 0.70-1.06). (García-Albéniz et al., 2021) The other concludes on the basis of low-grade evidence, that there may be no effect in prophylaxis of SARS-CoV-2 infection and furthermore no important effect on hospital admission. (Bartoszko et al., 2021) Of the RCTs investigating hydroxychloroquine as prophylaxis, four reported information on admissions. (Barnabas et al., 2020 , Boulware et al., 2020 , Mitjà et al., 2020 , Rajasingham et al., 2020 A total of 51 hospitalizations occurred across all four studies. Two trials, which were both on post-exposure prophylaxis, classified admissions on their relation to COVID-19. Both had an equal distribution of COVID-19 related admissions between the treatment and control arms. (Barnabas et al., 2020 , Rajasingham et al., 2020 Thus, despite the strong WHO recommendations, the evidence on the effect of hydroxychloroquine prophylaxis is subpar. When comparing the before mentioned results on SARS-CoV-2 to ours, the neutral results line up. However, due to the sparseness of data, a minor benefit of hydroxychloroquine cannot be ruled out. Especially regarding the effect on hospitalizations, the evidence is sparse and limited by few very events. However, the neutral results line up with our results which, although limited in power, report no difference in admissions following SARS-CoV-2.

Our study has some strengths. We used the Danish nationwide and complete registries which ensured a homogenous and complete availability of data in the cohort and thus there was no loss to follow-up. These data comprised all confirmed positive SARS-CoV-2 PCR-and antigen-tests performed through all public hospitals and public test centers in Denmark during the study, account for nearly all tests performed in Denmark. All positive PCR and antigen-tests performed in Denmark are required by law to be reported to Statens Serum Institut. The data also included all prescriptions collected from pharmacies on the defined pharmaceuticals and data on diagnosis registered at all in-patient and out-patient visits to hospitals in Denmark. Additionally, the study was conducted in a country with universal healthcare, free testing, and without any risk of third center referral bias. Availability of these data entailed a large cohort consisting of all recipients of hydroxychloroquine who had started the drug before the pandemic emerged in Denmark and the number of exposed, non-J o u r n a l P r e -p r o o f exposed, and the number of events, was in fact, larger than in any other published study. The size of the cohort makes it more generalizable amongst other populations. Furthermore, the Danish registries ensured no loss to follow up since all persons either admitted or dead are registered.

Despite the mentioned strengths, our study also has some limitations. First, the design of the primary analyses does not take into account that differences in behavior or living conditions of the groups could existillustrated by e.g. the decreased risk of SARS-CoV-2 in cancer patients. Using propensity-score matching for the sensitivity analyses will likely have reduced the effect of the two mentioned biases, although this is by far certain. Second, the availability of testing amongst the population represents a possible bias, especially in the beginning of the pandemic. A second wave hit Denmark in the fall of 2020, where testing possibilities were abundant, thus reducing this bias, data on the amount of testing performed in Denmark is supplied in Supplemental Data (Table S8 and Figure S4 ). Third, there is a possibility of residual confounding, but currently, no obvious connection exists between a known rheumatological disorder and the risk of contracting SARS-CoV-2. Fourth, due to a lack of data on the so-called biological agents (TNF-antagonists etc.) of the patients since data on biological treatment are not included in NPR, why we were not able to take the effect of these into account. Furthermore, we did not include data on dosing information, although it seems fair to assume that the treatment follows the Danish recommended doses of 200-400 mg hydroxychloroquine per day.(Rheumatology, 2019) Finally, it seems worth noting that although there seemed to be some discrete differences on some of the baseline variables in the propensity-matched cohort (table 1) , only methotrexate and systemic corticosteroids were of a mentionable difference.

In conclusion, we did not find any protective effect of primary prophylaxis with hydroxychloroquine against SARS-CoV-2 infection among pre-existing users of this drug.

Rather, very neutral estimates were seen in both primary and secondary analyses as well as the sensitivity analyses. Our findings are in congruence with small, randomized trials of primary and post-exposure prophylaxis as well as the living WHO guideline on the drugs to prevent COVID-19. Based on our study and the abundance of neutral data on hydroxychloroquine for COVID-19, this study does not support the use of hydroxychloroquine in the prophylaxis against SARS-CoV-2.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

This work was supported by The Novo Nordisk Foundation (Grant number: NNF20SA0062834). The research salary of PS was sponsored by Copenhagen University Hospital-Herlev and Gentofte. The trial is not supported in any way by the pharmaceutical industry. The funding sources have not had and will not have any influence on trial design, data collection, analysis, or reporting.

Statistical source code used for generation of the results can be obtained via the corresponding author. Source data collected for this study will not be made available for others due to the Danish legislation regarding data sharing on population data. However, Danish citizens who have a legitimate reason, can apply for access to the data via the Danish National Health Authority (https://sundhedsdatastyrelsen.dk/da/forskerservice/ansog-omdata). The study protocol is available at http://coptrin.dk/wpcontent/uploads/2020/08/hydrchloroq-profylakse-final.pdf. 

Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

Prophylaxis for covid-19: living systematic review and network meta-analysis

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

Systematic review and metaanalysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10131 US Veterans With SARS-CoV-2 Infection

Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study

A living WHO guideline on drugs to prevent covid-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Hydroxychloroquine in systemic lupus erythematosus (SLE)

Data Resource Profile: The Danish National Prescription Registry

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial

Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort

Behandling med hydroxychloroquin (Eng.: Treatment with Hydroxychloroquine)

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

The Danish Civil Registration System as a tool in epidemiology

The Danish National Patient Registry: a review of content, data quality, and research potential

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

MiBa Board of R. The Danish Microbiology Database (MiBa) 2010 to 2013

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)